NVO Company Profile and Key Details
NYSE : NVO
Novo Nordisk A/S
$50.43
1.66+3.40%
At Close 4:00 PM58.48
BESG ScoreESG Rating
Price Chart
Stock Price Today
Novo Nordisk A/S (NVO) stock surged +3.40%, trading at $50.43 on NYSE, up from the previous close of $48.77. The stock opened at $49.82, fluctuating between $49.79 and $50.90 in the recent session.
Stock Snapshot
48.77
Prev. Close
224.1B
Market Cap
49.79
Day Low
12.51
P/E Ratio
4.03
EPS (TTM)
15.68
Cash Flow per Share
49.82
Open
4.44B
Number of Shares
50.895
Day High
100%
Free Float in %
23.87
Book Value
11.77M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 02, 2026 | 49.82 | 50.90 | 49.78 | 50.43 | 11.78M |
| Jul 01, 2026 | 49.02 | 49.55 | 48.61 | 48.77 | 11.03M |
| Jun 30, 2026 | 48.51 | 48.62 | 47.87 | 47.94 | 8.58M |
| Jun 29, 2026 | 47.72 | 48.48 | 47.61 | 48.34 | 8.22M |
| Jun 26, 2026 | 47.12 | 48.50 | 46.99 | 48.07 | 20.13M |
| Jun 25, 2026 | 47.82 | 48.24 | 47.32 | 47.64 | 10.53M |
| Jun 24, 2026 | 47.10 | 47.65 | 47.02 | 47.41 | 15.04M |
| Jun 23, 2026 | 46.80 | 47.43 | 46.44 | 47.42 | 17.59M |
| Jun 22, 2026 | 44.01 | 46.45 | 43.90 | 45.90 | 17.05M |
| Jun 18, 2026 | 43.45 | 44.00 | 42.52 | 43.19 | 8.98M |
| Jun 17, 2026 | 44.97 | 45.00 | 43.46 | 43.52 | 9.83M |
| Jun 16, 2026 | 44.03 | 44.11 | 43.36 | 43.55 | 7.05M |
| Jun 15, 2026 | 44.69 | 44.79 | 43.81 | 43.92 | 10.07M |
| Jun 12, 2026 | 43.94 | 44.60 | 43.72 | 43.88 | 14.67M |
| Jun 11, 2026 | 42.97 | 44.11 | 42.94 | 43.96 | 12.52M |
| Jun 10, 2026 | 41.67 | 44.03 | 41.66 | 42.81 | 16.42M |
| Jun 09, 2026 | 41.08 | 42.31 | 41.08 | 42.19 | 14.56M |
| Jun 08, 2026 | 42.22 | 42.41 | 41.00 | 41.02 | 20.52M |
| Jun 05, 2026 | 44.05 | 44.22 | 42.86 | 42.96 | 10.48M |
| Jun 04, 2026 | 43.09 | 44.37 | 42.22 | 43.75 | 14.65M |
Contact Details
About Company
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Company Information
| Employees | 77406 |
| Beta | 0.35 |
| Sales or Revenue | $232.26B |
| 5Y Sales Change% | 1.242% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Stock Peers
LLY
18.76+1.57%
Eli Lilly and Company$1,210.50JNJ9.06001+3.57%
Johnson & Johnson$263.04ABBV10.01001+3.99%
AbbVie Inc.$261.07AZN11.29+6.14%
AstraZeneca PLC$195.15NVS5.76+3.74%
Novartis AG$159.90MRK4.14999+3.31%
Merck & Co., Inc.$129.52ZTS2.35+3.24%
Zoetis Inc.$74.80BMY1.69+2.99%
Bristol-Myers Squibb Company$58.13GSK2.36+4.60%
GSK plc$53.66PFE0.44+1.84%
Pfizer Inc.$24.32Company Overview
Novo Nordisk A/S (NYSE:NVO) closed at $50.43 USD, gaining $1.66 (3.40%) from the previous close of $48.77. The stock is currently mid-range between its 52-week high and low $35.12 and $71.80. With a market capitalization of about $224.10 billion, Novo Nordisk A/S is classified as a mega-cap and shows lower-than-market volatility (beta ~0.36). Key stats such as the average daily volume over the past year has been around 14.87 million shares, in line with its 52-week average. Headquartered in Bagsvaerd, None, Novo Nordisk A/S operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Maziar Mike Doustdar, the company employs approximately 77,406 people and listed since April 30, 1981. Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint.
Technical Performance
Short-term trend indicators are bullishly aligned (SMA20 -21.65%, SMA50 -28.41%, SMA200 -34.36%). The stock’s 14-day RSI is 24.12 (weak momentum), while the ATR of 2.25 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -59.06% below its high and over -0.08% above its low. Average 10-day trading volume of 11.71 million shares is below the 3-month average of 14.13 million, indicating normal recent market interest.
Valuation Metrics
Novo Nordisk A/S trades at a P/E ratio of 12.0, slightly below the S&P 500 average, with a price-to-sales ratio of 4.47 and a price-to-book ratio of 7.21 trading at moderately above to book value. The P/FCF stands at 47.19, also above market averages.
Dividend & Fair Value
Novo Nordisk A/S last paid a dividend of 1.8 per share, this equals a trailing yield of roughly 7.22%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $74.76. This means the shares are trading below this model’s fair value.
Shareholding & Insider Activity
Novo Nordisk A/S has 3.37 billion shares outstanding. The public float is 3.19 billion shares, elevated short interest at 0.62% of float. This equals 21.02 million shares. The short ratio is 0.89 days. Institutional investors hold 9.36% of the float. Insiders own 0.01%.
Financial & Profitability Overview
On valuation metrics, Novo Nordisk A/S trades at a P/E of 12.01, P/S of 4.47 and P/B of 7.21. Liquidity is tight, with a current ratio of 0.79 and quick ratio of 0.56. Operationally, the company’s inventory turnover is 1.16 and cash conversion cycle is -395.71 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.72, supported by a cash flow-to-debt ratio of 0.81.
Quarterly Financial Highlights
The company ended the quarter with $30.23B in cash and short-term investments, a total debt of $27.01B, and net debt of $12.61B. Total assets were $314.49B, with equity of $106.56B. Financials further reflected robust performance, with operating cash flow of $108.91B, free cash flow of $70.01B, and capital expenditures of - $38.90B.
Price Forecast & Outlook
Our AI price prediction model suggests that Novo Nordisk A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.37%, with price expected at $54.65 by July 16, 2026, within a range of $53.45 to $55.82 3-Month Outlook: Projected fall of -0.5%, reaching $50.18 by September 30, 2026, with a range of $45.87 to $53.31. 1-Year Outlook: Projected loss of -50.86%, with price at $24.78 by July 02, 2027, within a range of $15.17 to $32.63.
Key Takeaways
Novo Nordisk A/S (NYSE:NVO) shares are up 19.26% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Novo Nordisk A/S trading at a premium to the broader market with a P/E of 12.0. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $111.14, suggesting 120.38% upside. Our AI forecast model points to short-term strength (8.37% over two weeks), a medium-term fall (-0.5% over three months), and a longer-term loss (-50.86% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Novo Nordisk A/S (NVO) stock price?
Novo Nordisk A/S (NYSE: NVO) stock price is $50.43 in the last trading session. During the trading session, NVO stock reached the peak price of $50.90 while $49.79 was the lowest point it dropped to. The percentage change in NVO stock occurred in the recent session was 3.4% while the dollar amount for the price change in NVO stock was $1.66.
NVO's industry and sector of operation?
The NYSE listed NVO is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Novo Nordisk A/S designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of NVO?
No Data
How NVO did perform over past 52-week?
NVO's closing price is 43.59% higher than its 52-week low of $35.12 where as its distance from 52-week high of $71.80 is -29.76%.
How many employees does NVO have?
Number of NVO employees currently stands at 77,406.
Link for NVO official website?
Official Website of NVO is: https://www.novonordisk.com
How do I contact NVO?
NVO could be contacted at phone 454 444 8888 and can also be accessed through its website. NVO operates from Novo Alle 1, Bagsvaerd, 2880, Denmark.
How many shares of NVO are traded daily?
NVO stock volume for the day was 11.77M shares. The average number of NVO shares traded daily for last 3 months was 14.87M.
What is the market cap of NVO currently?
The market value of NVO currently stands at $224.10B with its latest stock price at $50.43 and 4.44B of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep